{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma+Tumor+Recurrence&page=6", "query": { "condition": "Glioma Tumor Recurrence", "page": 6 }, "page_size": 10 }, "pagination": { "page": 6, "page_size": 10, "total_count": 1022, "total_pages": 103, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma+Tumor+Recurrence&page=7&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Glioma+Tumor+Recurrence&page=5&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-07T03:46:39.366Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00503204", "title": "Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma", "Brain Tumor" ], "interventions": [ { "name": "Cediranib", "type": "DRUG" }, { "name": "Lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2007-09", "completion_date": "2008-12", "has_results": false, "last_update_posted_date": "2009-11-25", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00503204" }, { "nct_id": "NCT05370508", "title": "A Study of Sonodynamic Therapy Using SONALA-001 and Exablate 4000 Type 2.0 in Subjects With Recurrent GBM", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Recurrent GBM" ], "interventions": [ { "name": "SONALA-001 (ALA) and MR-Guided Focused Ultrasound device (MRgFUS)", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "SonALAsense, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 8, "start_date": "2023-02-06", "completion_date": "2024-07-08", "has_results": false, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 6, "location_summary": "Phoenix, Arizona • San Francisco, California • Rochester, Minnesota + 3 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Francisco", "state": "California" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05370508" }, { "nct_id": "NCT02194452", "title": "Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acoustic Schwannoma", "Adult Anaplastic Astrocytoma", "Adult Anaplastic Ependymoma", "Adult Anaplastic Meningioma", "Adult Anaplastic Oligodendroglioma", "Adult Brain Stem Glioma", "Adult Choroid Plexus Tumor", "Adult Craniopharyngioma", "Adult Diffuse Astrocytoma", "Adult Ependymoblastoma", "Adult Ependymoma", "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma", "Adult Grade I Meningioma", "Adult Grade II Meningioma", "Adult Medulloblastoma", "Adult Meningeal Hemangiopericytoma", "Adult Mixed Glioma", "Adult Myxopapillary Ependymoma", "Adult Oligodendroglioma", "Adult Papillary Meningioma", "Adult Pilocytic Astrocytoma", "Adult Pineal Gland Astrocytoma", "Adult Pineoblastoma", "Adult Pineocytoma", "Adult Subependymal Giant Cell Astrocytoma", "Adult Subependymoma", "Adult Supratentorial Primitive Neuroectodermal Tumor (PNET)", "Childhood Choroid Plexus Tumor", "Childhood Craniopharyngioma", "Childhood Ependymoblastoma", "Childhood Grade I Meningioma", "Childhood Grade II Meningioma", "Childhood Grade III Meningioma", "Childhood High-grade Cerebellar Astrocytoma", "Childhood High-grade Cerebral Astrocytoma", "Childhood Infratentorial Ependymoma", "Childhood Low-grade Cerebellar Astrocytoma", "Childhood Low-grade Cerebral Astrocytoma", "Childhood Medulloepithelioma", "Childhood Supratentorial Ependymoma", "Meningeal Melanocytoma", "Newly Diagnosed Childhood Ependymoma", "Recurrent Adult Brain Tumor", "Recurrent Childhood Anaplastic Astrocytoma", "Recurrent Childhood Anaplastic Oligoastrocytoma", "Recurrent Childhood Anaplastic Oligodendroglioma", "Recurrent Childhood Brain Stem Glioma", "Recurrent Childhood Cerebellar Astrocytoma", "Recurrent Childhood Cerebral Astrocytoma", "Recurrent Childhood Diffuse Astrocytoma", "Recurrent Childhood Ependymoma", "Recurrent Childhood Fibrillary Astrocytoma", "Recurrent Childhood Gemistocytic Astrocytoma", "Recurrent Childhood Giant Cell Glioblastoma", "Recurrent Childhood Glioblastoma", "Recurrent Childhood Gliomatosis Cerebri", "Recurrent Childhood Gliosarcoma", "Recurrent Childhood Medulloblastoma", "Recurrent Childhood Oligoastrocytoma", "Recurrent Childhood Oligodendroglioma", "Recurrent Childhood Pilocytic Astrocytoma", "Recurrent Childhood Pilomyxoid Astrocytoma", "Recurrent Childhood Pineoblastoma", "Recurrent Childhood Pleomorphic Xanthoastrocytoma", "Recurrent Childhood Protoplasmic Astrocytoma", "Recurrent Childhood Subependymal Giant Cell Astrocytoma", "Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor", "Recurrent Childhood Visual Pathway and Hypothalamic Glioma", "Recurrent Childhood Visual Pathway Glioma", "Untreated Childhood Anaplastic Astrocytoma", "Untreated Childhood Anaplastic Oligodendroglioma", "Untreated Childhood Brain Stem Glioma", "Untreated Childhood Cerebellar Astrocytoma", "Untreated Childhood Cerebral Astrocytoma", "Untreated Childhood Diffuse Astrocytoma", "Untreated Childhood Fibrillary Astrocytoma", "Untreated Childhood Gemistocytic Astrocytoma", "Untreated Childhood Giant Cell Glioblastoma", "Untreated Childhood Glioblastoma", "Untreated Childhood Gliomatosis Cerebri", "Untreated Childhood Gliosarcoma", "Untreated Childhood Medulloblastoma", "Untreated Childhood Oligoastrocytoma", "Untreated Childhood Oligodendroglioma", "Untreated Childhood Pilocytic Astrocytoma", "Untreated Childhood Pilomyxoid Astrocytoma", "Untreated Childhood Pineoblastoma", "Untreated Childhood Pleomorphic Xanthoastrocytoma", "Untreated Childhood Protoplasmic Astrocytoma", "Untreated Childhood Subependymal Giant Cell Astrocytoma", "Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor", "Untreated Childhood Visual Pathway and Hypothalamic Glioma", "Untreated Childhood Visual Pathway Glioma" ], "interventions": [ { "name": "gallium Ga 68-edotreotide", "type": "RADIATION" }, { "name": "positron emission tomography", "type": "PROCEDURE" }, { "name": "computed tomography", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "RADIATION", "PROCEDURE", "OTHER" ], "sponsor": "Sue O'Dorisio", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "29 Years", "sex": "ALL", "summary": "6 Months to 29 Years" }, "enrollment_count": 0, "start_date": "2013-09", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2017-04-28", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 1, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT02194452" }, { "nct_id": "NCT03220035", "title": "Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma", "Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma", "Ependymoma", "Ewing Sarcoma", "Hepatoblastoma", "Langerhans Cell Histiocytosis", "Malignant Germ Cell Tumor", "Malignant Glioma", "Osteosarcoma", "Peripheral Primitive Neuroectodermal Tumor", "Recurrent Childhood Central Nervous System Neoplasm", "Recurrent Childhood Non-Hodgkin Lymphoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Neuroblastoma", "Refractory Malignant Solid Neoplasm", "Refractory Neuroblastoma", "Refractory Non-Hodgkin Lymphoma", "Refractory Primary Central Nervous System Neoplasm", "Rhabdoid Tumor", "Rhabdomyosarcoma", "Soft Tissue Sarcoma", "Wilms Tumor" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Vemurafenib", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Months", "maximum_age": "21 Years", "sex": "ALL", "summary": "12 Months to 21 Years" }, "enrollment_count": 4, "start_date": "2017-11-08", "completion_date": "2024-12-31", "has_results": true, "last_update_posted_date": "2025-01-27", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 114, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 90 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03220035" }, { "nct_id": "NCT00805376", "title": "DNX-2401 (Formerly Known as Delta-24-RGD-4C) for Recurrent Malignant Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Brain Cancer", "Central Nervous System Diseases" ], "interventions": [ { "name": "DNX-2401", "type": "DRUG" }, { "name": "Tumor Removal", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "DNAtrix, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2009-02", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2018-07-16", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00805376" }, { "nct_id": "NCT00066248", "title": "Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor", "Central Nervous System Tumors", "Cachexia", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cyproheptadine hydrochloride", "type": "DRUG" }, { "name": "megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 70, "start_date": "2003-06", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 40, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066248" }, { "nct_id": "NCT01906385", "title": "Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Glioma" ], "interventions": [ { "name": "Rhenium Liposome Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cerenome", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 55, "start_date": "2015-06-03", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-03-26", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 3, "location_summary": "Manhasset, New York • Dallas, Texas • San Antonio, Texas", "locations": [ { "city": "Manhasset", "state": "New York" }, { "city": "Dallas", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01906385" }, { "nct_id": "NCT00586508", "title": "Trial of Enzastaurin and Bevacizumab in Participants With Recurrent Malignant Gliomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "enzastaurin", "type": "DRUG" }, { "name": "bevacizumab", "type": "DRUG" }, { "name": "Enzyme-inducing antiepileptic drugs (EIAED)", "type": "DRUG" }, { "name": "Non-enzyme inducing antiepileptic drugs (NEIAED)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 81, "start_date": "2007-11", "completion_date": "2013-10", "has_results": true, "last_update_posted_date": "2020-09-24", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00586508" }, { "nct_id": "NCT03834740", "title": "A Phase 0/I Study of Ribociclib (LEE011) in Combination With Everolimus in Preoperative Recurrent High-Grade Glioma Patients Scheduled for Resection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma Multiforme", "Glioma of Brain" ], "interventions": [ { "name": "Ribociclib", "type": "DRUG" }, { "name": "Everolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "St. Joseph's Hospital and Medical Center, Phoenix", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2019-01-19", "completion_date": "2022-02-18", "has_results": true, "last_update_posted_date": "2025-05-30", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 3, "location_summary": "Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona", "locations": [ { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03834740" }, { "nct_id": "NCT06389591", "title": "RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM)", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Glioblastoma" ], "interventions": [ { "name": "pp65 RNA loaded lipid particles, pp65 RNA-LPs (Drug Product 1 or DP1)", "type": "BIOLOGICAL" }, { "name": "RNA loaded lipid particles, RNA-LPs (Drug Product 2 or DP2)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 24, "start_date": "2024-12-02", "completion_date": "2027-12-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-07T03:46:39.366Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06389591" } ] }